A few days ago, China was told that the Coronavirus, a drug used for a new type of influenza in Japan, is proving effective.
On the occasion, Zheng Shin Min, an official at the Chinese Ministry of Science and Technology, said the effects of a drug called favipiravir have been encouraging during clinical trials in Wuhan and Shenzhen.
The drug was used in 340 patients and the official said ‘it has proven to be very effective in treating it with being very safe’.
Now the results of this research trial have been released, which can help to know how effective it can be.
The team from the National Clinical Research Center for Infectious Diseases at Shenzhen’s Third People’s Hospital published the results in the journal, Journal of Engineering.
Favipiravir is probably effective against the new Coronavirus.
In this study, 35 patients infected with COVID-19 at the beginning of February used 1600 mg favipiravir 2 times (in 2 different doses) on the first day while interferon was also administered.
The dose was reduced to 600 mg on the second day and 2 times a day and the use of interferon continued. Another group of 45 patients was administered Favipiravir 400 mg for 14 days and then 100 mg twice daily with interferon.
Researchers discovered that the people who were using Favipiravir got a virus clearance on average 4 days while in the other group it happened in 11 days.
Similarly, more than 91% of the patients in the favipiravir group showed improvement in lung condition while in the other group the rate was close to 63%.
Researchers say these data prove that the drug cleanses the virus faster, with fewer side effects discovered so far.
He said it was a controlled study that showed that Favipiravir could be a good treatment for COVID-19.
How reliable are the results?
According to the medical experts, since this research was done on a very limited scale, the results are encouraging but more work needs to be done in this regard.
Because the patients’ ages in both groups differed significantly while some other factors also needed attention, better trials were needed, Only then can the general patient consider using this medicine.
Is it being used anywhere else?
In Japan, too, the drug is being used for clinical trials on patients with minor symptoms of the Coronavirus, and they are expected to prevent the development of the virus in patients. ۔
But sources from the Japanese Ministry of Health say the drug is not likely to be effective for patients with serious symptoms as it has not been seen in patients in whom the virus has spread.
This new drug will require government approval to use it extensively for the new Novel Coronavirus disease COVID-19, as it was originally designed to treat the flu.
A Japanese Ministry of Health official told local media that the use of this drug for Code 19 patients may be approved until May, but if the clinical research results are delayed, the approval process may be delayed.
It is important to note that COVID-19 is not currently treated, but its symptoms are treated with different medicines depending on their nature and the World Health Organization says that 97% of the patients also recover.
Vaccines are being prepared in different countries for this, while testing for human vaccines has begun in the United States, but the general availability of a vaccine will require a period of one and a half years.
Considering that the number of Coronavirus cases is increasing in Pakistan, the number of virus-infected people has increased to 1670 in the country.
The highest number of Corona cases were reported in Punjab province with 638 reported while Sindh was second with 508 cases, Khyber Pakhtunkhwa with 195 and Balochistan with 144, Gilgit-Baltistan 128 and Islamabad 51 and Azad Kashmir 6 cases have emerged.
So far 19 patients have been killed and 28 have recovered.
On the other hand, the number of Coronavirus cases worldwide has risen to 737,577, while more than 35,000 have died.
Report on The Experimental Drug Really Effective???